Kalytera Therapeutics Overview
Kalytera Therapeutics Inc is a clinical-stage pharmaceutical company developing next-generation cannabinoid therapeutics. Kalytera develops novel cannabinoid medicines for a range of medical needs with an initial focus on graft-versus-host disease (GvHD). Kalytera also develops a new class of proprietary cannabidiol (CBD) therapeutics. Kalytera acquired its GvHD program from Israel-based Talent Biotechs in early 2017 based on the results of Talents' four phase-2a clinical studies in the prevention and treatment of GvHD using CBD.
Latest News
growth-negative
Kalytera Therapeutics Inc. (TSXV:KLY) completes name change to Claritas Pharmaceuticals, Inc.
Kalytera Therapeutics Inc. has changed its name to Claritas Pharmaceuticals, Inc. The company intends to focus on developing its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 and other viral infections. The ticker symbol will change to CLAS pending final approval of the TSX Venture Exchange. Shareholders will receive letters of transmittal to exchange their current share certificates for certificates with the new name. The company will hold its annual and special meeting of shareholders on June 17, 2021. Claritas Pharmaceuticals is a clinical-stage biopharmaceutical company.
Management Changes
growth-positive
http://www.marketwired.com/press-release/santa-maria-petroleum-inc-kalytera-therapeutics-inc-announce-signing-merger-agreement-tsx-venture-smq.h-2173009.htm
The article discusses the services offered by GlobeNewswire, a press release distribution company. It highlights the importance of media relations in PR and offers insights from a PRWeek/Notified survey. GlobeNewswires services include targeted distribution options for sharing news with media, investors, and consumers, a media contacts database, and a PR platform that integrates social listening and media monitoring. The company also partners with various media outlets, including Business Headline, a news publication based in Jaipur, India.
CustomersPartners
Neutral
Form D filed by SANTA MARIA PETROLEUM INC. on 2016-10-07
Santa Maria Petroleum Inc. has filed a notice of exempt offering of securities with the United States Securities and Exchange Commission. The company, which is based in Ontario, Canada, has sold securities to the value of $536,314. The offering is not being made in connection with a business combination transaction such as a merger or acquisition. The securities have been sold to nine investors.
Investment
Team Members
0
Employees: 1-10
Web & Social Links
| Website | kalytera.co |
Locations
Katzrin, Israel
Photos & Videos
No files yet